First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

被引：3
|
作者：
Yang, Shuang [1 ]
Feng, Weineng [1 ]
Deng, Yanming [1 ]
Liang, Jianmiao [1 ]
机构：
[1] First Peoples Hosp Foshan, Dept Head Neck & Thorac Oncol, Foshan, Peoples R China
来源：
WORLD JOURNAL OF SURGICAL ONCOLOGY | 2023年 / 21卷 / 01期
关键词：
Ensartinib; ALK rearranged; ALK I1171N; Lung caner;
D O I：
10.1186/s12957-023-02935-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BackgroundThe acquired resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK-rearranged NSCLC is associated with poor survival outcomes and poses distinct clinical challenges. It is essential to develop potential therapeutic strategies for overcoming resistance.Case presentationHere, we first report a female lung adenocarcinoma patient with an acquired ALK resistance mutation (ALK 11171N) who was treated with ensartinib. Her symptoms significantly improved after only 20 days, and with a side effect of mild rash. Follow-up images observed no further brain metastases after 3 months.ConclusionsThis treatment may provide a new therapeutic strategy for ALK TKIs resistant patients, especially in position 1171 of ALK exon20.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
    Shuang Yang
    Weineng Feng
    Yanming Deng
    Jianmiao Liang
    World Journal of Surgical Oncology, 21
  • [2] First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report
    Scarfone, Giovanna
    Fumagalli, Monica
    Imbimbo, Martina
    Ceruti, Tommaso
    Cribiu, Fulvia Milena
    Di Loreto, Eugenia
    D'Incalci, Maurizio
    Facchin, Federica
    Fontana, Camilla
    Garassino, Marina C.
    Peccatori, Fedro A.
    Persico, Nicola
    Signorelli, Diego
    Zucchetti, Massimo
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 873 - 877
  • [3] Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
    Ye, Zhifeng
    Guo, Junhua
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] ALK-rearranged squamous cell lung cancer: a case report
    Zhang, Quan
    Wang, Jinghui
    Zhang, Shucai
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (02): : 2195 - 2198
  • [5] A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
    Kashima, Jumpei
    Okuma, Yusuke
    Hishima, Tsunekazu
    ONCOTARGETS AND THERAPY, 2016, 9 : 6059 - 6063
  • [6] Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report
    Siblini, Laura
    Schott, Roland
    Trensz, Philippe
    Pencreach, Erwan
    Bender, Laura
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2342 - 2346
  • [7] Identification of a Novel HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib
    Ou, Sai-Hong Ignatius
    Klempner, Samuel J.
    Greenbowe, Joel R.
    Azada, Michele
    Schrock, Alexa B.
    Ali, Siraj M.
    Ross, Jeffrey S.
    Stephens, Philip J.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (12) : 1821 - 1825
  • [8] Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
    Leung, Jackson Ka Chun
    Kwok, Wang Chun
    Leung, Arthur Chun Fung
    Tsui, Po
    Ho, James Chung-Man
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (07):
  • [9] Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report
    Hu, Jia
    Zhang, Baoshi
    Yao, Fangfang
    Fu, Yan
    Chen, Dianjun
    Li, Donghui
    Du, Nan
    Lizaso, Analyn
    Song, Jinlei
    Zhang, Lu
    Li, Xiaosong
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14
  • [10] Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report
    Emelie Gezelius
    Maria Planck
    Bassam Hazem
    Seema Nagpal
    Heather Wakelee
    Cancer Chemotherapy and Pharmacology, 2025, 95 (1)
12345